Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agenus Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

65 comunicati stampa

Guarda tutti i comunicati
21/04/2026
Web e Social Network
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
17/04/2026
Eventi
Industria
Biotecnologia
Salute
Oncologia
Medicina - Varie
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
01/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
26/03/2026
Web e Social Network
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
16/03/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
10/03/2026
Industria
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Scienza
Oncologia
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
21/01/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Biotecnologia
Salute
Oncologia
Web e Social Network
Agenus to Host First 2026 Stakeholder Webcast
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
15/01/2026
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Industria
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0